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OBJECTIVES: Although liver transplantation procedures are common and highly expensive, their cost structure is
still poorly understood. This study aimed to develop models of micro-costs among patients undergoing liver
transplantation procedures while comparing the role of individual clinical predictors using tree regression
models.
METHODS: We prospectively collected micro-cost data from patients undergoing liver transplantation in a
tertiary academic center. Data collection was conducted using an Intranet registry integrated into the insti-
tution’s database for the storing of financial and clinical data for transplantation cases.
RESULTS: A total of 278 patients were included and accounted for 300 procedures. When evaluating specific
costs for the operating room, intensive care unit and ward, we found that in all of the sectors but the ward,
human resources were responsible for the highest costs. High cost supplies were important drivers for the
operating room, whereas drugs were among the top four drivers for all sectors. When evaluating the predictors
of total cost, a MELD score greater than 30 was the most important predictor of high cost, followed by a Donor
Risk Index greater than 1.8.
CONCLUSION: By focusing on the highest cost drivers and predictors, hospitals can initiate programs to reduce
cost while maintaining high quality care standards.
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’ INTRODUCTION
More than 6,000 liver transplant procedures are performed
in the United States every year (1). Despite being common,
liver transplants are among the most expensive procedures
in abdominal surgery (2), and the sources of these costs are
still poorly understood, especially in developing countries.
Specifically, and to our knowledge, no previous articles have
attempted to use prospectively collected micro-costing data
to predict individual patient costs while also using tree
regression models to evaluate the contribution of individual
factors in Latin America.
The average cost for liver transplantation has been estimated
at Can $89,066 and ranges from Can $30,505 to Can $690,431 (3),
although this cost structure varies across countries. For example,
a recent systematic review found a major cost difference
between the United States and other OECD (Organization
for Economic Co-operation and Development) countries, with
values of US $163,438 (US $145,277-181,598) and US $103,548
(US $85,514-$121,582) (4), respectively. Regardless of the under-
lying variation across countries, liver transplantation is an
expensive procedure (5). The sources of these high costs are
not well understood, with some authors reporting that
transplant admission charges alone represent as much as
50% of the total cost (6). When accounting for the total cost,
it has also been reported that the total hospital costs and
reimbursements are substantially increased when patients
have additional complications (7). Furthermore, the highest
expenses for this procedure vary widely as a function of
the underlying etiology, e.g., substantial differences exist
between patients with a diagnosis of hepatitis B and those
with hepatocellular carcinoma (8).
Accurately predicting individual patient cost is important
because transplantations are expensive procedures with sig-
nificant cost variation. Some authors have suggested sim-
plified formulas for the overall procedure cost. Brown et al.
proposed that final charges (US $) for liver transplants could
be calculated through the following formula: 3,407  bloodDOI: 10.6061/clinics/2017(06)02
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urea nitrogen + 74,474  UNOS (United Network for Organ
Sharing) status 1+ 102,662. Importantly, blood urea nitro-
gen and UNOS status are the only variables in this equation
(9). In another model, Axelrod predicted that the higher the
patient’s MELD (Model for End-Stage Liver Disease) score,
the more the patient would be charged for the surgical
procedure (10). In addition, having a severe liver disease,
cytomegalovirus infection, additional operative procedures,
and biliary complications are all predictors of increased cost
(3). Other models have focused on utilization metrics as the
primary predictors, using simple formulas in which the
duration of the pre-transplant stay in the intensive care unit,
age, body mass index, and calculated MELD scores are all
used to predict cost after transplantation (11). Finally, some
models have attempted to predict costs using variables such
as graft type, height, race, hepatic artery thrombosis, early
allograft rejection, and participation in a transition to home
program (12). Since these previous attempts to predict
cost are all based on traditional modeling techniques, the
final estimation is limited by the accuracy of the individual
variables.
To address this gap, the objective of this study was to
develop a series of predictive models that permit an evalua-
tion of individual clinical variables in the prediction of dif-
ferent cost components.
’ METHODS
Our objective was to develop a series of predictive models
for liver transplantation micro-costs based on a prospective
registry with consecutive patients. Our modeling strategy is
based on the TRIPOD statement (13).
Ethics
Approval was obtained from the Institutional Review Board
of the School of Medicine of the University of São Paulo
(HCFMUSP).
Setting
All of the data were collected from patients visiting
a single, tertiary, outpatient clinic at the University of São
Paulo. These patients were followed throughout the entire
care pathway, and the data collected included intra-operative
data. Data collection was conducted using an Intranet
registry that was integrated into the institution’s adminis-
trative data collection system. These systems are used for the
storage of financial and clinical information for transplantation
cases because the hospital receives funding from the National
Health System (NHS) for transplant procedures. Registration,
consultations, hospitalizations, medications and the materials
used were all tracked for liver transplantation cases. In addi-
tion, a dedicated research staff was responsible for collect-
ing a detailed list of material consumption, equipment, and
medications, among other cost items. A debit card was used
for all purchases; therefore, all price-related information was
available. Individual patients’ expenses for all components
were prospectively calculated during their in-hospital period
and then updated daily. Participant accrual occurred between
January 2012 and December 2014. The team performing the
transplantation was the same throughout the study period.
Participants
We included all adult patients above the age of 18 under-
going liver transplantation. These cases included standard,
living donor, combined transplantation (liver and kidney)
and re-transplantation. All of the procedures were conducted
at our center.
Outcomes
All of the costs from enrollment to transplantation and the
post-transplantation period (in-hospital period) were captured
in real time. We measured costs related to provider visits, pre-
operative tests, management of comorbidities and complications,
hospitalizations, and general costs during the post-transplant
period. These data were categorized as total cost, margins,
revenue, and costs specific to the operating room (laboratory,
gases, equipment, blood services, materials, drugs, human
resources, high-end supplies, and standard equipment), the
ICU (laboratory, dialysis, endoscopy, per diem, equipment,
imaging, blood services, gases, materials, drugs, food, human
resources, and intensive care unit), and the ward (pathology,
gases, equipment, dialysis, per diem, electricity, phone charges,
cleaning services, infrastructure and administrative support,
endoscopy, imaging, laboratory, blood services, materials, drugs,
food, and human resources). The costs of human resources
(doctors, nurses, nursing assistants, physical therapy, nutrition-
ists, social workers and psychologists) were calculated as the cost
time per professional, and the time was defined as the hours
dedicated by the professional for each specific liver trans-
plant patient. The costs were converted from Brazilian reais
to US dollars at a 3.69 rate (2015-11-04).
Predictors
After a detailed review of the available evidence on pre-
dictors of the cost of liver transplantation, we used clinical
judgment and the previous literature to select our variables (6,14).
Specifically, we selected the following variables: length of
stay (intensive care unit, ward, and total) and clinical pre-
dictors such as age, gender, body mass index, transplant type
(standard, living donor, re-transplantation, or combined
transplantation), MELD score, liver disease etiology (viral
hepatitis, alcoholic cirrhosis, primary sclerosing cholangitis,
and hepatocellular carcinoma), liver disease complications,
comorbidities (diabetes, hypertension, and renal failure among
others) and post-operative complications (rejection, kidney
failure, and infection), outcomes (discharge, death or
re-transplant), and cause of death (shock and septicemia).
Data analysis
We started the analysis by performing a graphical explor-
atory analysis evaluating frequency, percentage and near-
zero variance for categorical variables, distribution for numeric
variables, and missing values and patterns across all vari-
ables (15). Median values were used for stratification to
enable a similar frequency across comparison groups. Patients
were excluded from the analyses when missing values were
required. For example, when stratifying an analysis by the
MELD score, patients with missing values for the MELD score
were excluded. This exclusion accounts for the inequality in
the total number of samples in all of the tables.
We used linear regression models for the analysis. All of
the results were reported as predicted medians with 95%
confidence intervals. Tree regression pruning was based on
the following algorithm: at each pair of nodes from a
common parent, we assessed the error based on the testing
data and specifically evaluated whether the sum of squares
would decrease if the two nodes were removed. In the case
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of a positive answer, the nodes were removed; otherwise,
they were left intact. Although tree regression models
represent the best cut-points for the values predicting the
outcomes, in contrast with linear regression models, their
results cannot be represented in a single equation. However,
these models have a graphical representation that we present
along with the interpretation of our results. All of the
analyses were performed with the R statistical language and
using regression trees based on the rpart package.
’ RESULTS
A total of 278 patients were included and accounted for
300 procedures. Most patients were male (63.7%) with a
mean age of 52.32+/- 13.68 years and a body mass index of
25.89 +/- 5.96. When evaluating the procedures (Table 1),
most of them were standard transplants (78.1%) with a mean
Donor Risk Index (DRI) of 1.43 (+/- 0.31). The average
length of stay was close to 21 days, with more than 9 days
spent in the intensive care unit. One-fifth of our subjects died
after the procedure, and approximately ten percent of all
patients had to undergo a re-transplant. MELD scores greater
than the median value in this sample (cut point at 30) were
associated with higher rates of mortality and total costs.
When evaluating specific costs for the operating room,
intensive care unit and ward (transplant unit floor), we found
that in all sectors but the ward, human resources were
responsible for the highest costs. High cost supplies were
important drivers for the operating room, whereas drugs
were among the top four drivers for all sectors. Higher
MELD scores were associated with increased costs for high-
cost supplies, blood services and labs in the operating room,
and several types of costs occurred in the intensive care unit
and ward (Table 2).
When comparing specific components of the total, pre-
dicted, and adjusted cost in patients with high MELD scores,
patients with MELD functional scores greater than 30 pre-
sented significantly higher total costs (Table 3).
We then evaluated specific predictors of total costs asso-
ciated with all baseline information, etiology, comorbidities,
and complications. We found that a MELD score greater than
30 was the single most important predictor of costs, with
the highest costs accompanying a MELD score greater than
30 and coupled to a DRI greater than 1.8 (Figure 1). This
regression tree can be interpreted by following the patient
characteristics from left to right. For example, if the MELD
was less than 30 and if post-transplant kidney failure is
absent, then the patient has a 54% chance of having costs
among the top 50th percentile.
As demonstrated in our tables in the appendix, when
evaluating the total costs with respect to specific conditions,
patients with hepatocellular carcinoma were associated with
lower operating room, intensive care unit and ward costs;
patients with primary sclerosing cholangitis were associated
with lower intensive care unit costs; and patients with portal
vein thrombosis were associated with higher total costs.
In addition, death was also associated with an increased total
cost of transplantation. Finally, linear regression modeling
demonstrated that the time spent in the operating room was
significantly associated with higher transplantation costs
(po0.001), whereas no statistically significant associations
were found between costs, MELD score (p=0.724), and DRI
(p=0.351).
’ DISCUSSION
To the best of our knowledge, this is the first study uti-
lizing tree regression models to focus on individual cost
drivers after a liver transplant. When evaluating specific
costs for the operating room, intensive care unit, and ward
(transplantation unit floor), we found that in all sectors but
the ward, human resources were responsible for the highest
costs. High-cost supplies were important drivers for the
operating room, whereas drugs were among the top four
drivers for all sectors. When evaluating the predictors of total
cost, a MELD score greater than 30 was the most important
predictor of cost, with the highest costs accompanying a
MELD greater than 30 and coupled with a DRI greater than 1.8.
To understand the cost structure related to liver trans-
plants in Brazil, it is important to provide a context regarding
the organ allocation system. Specifically, organs are allocated
in Brazil based on the MELD score and blood type com-
patibility. Patients with hepatocellular carcinoma, refractory
ascites, disabling encephalopathy, recurrent cholangitis and
other specific diagnoses receive special attention and are moved
to the top of the transplantation list. Others are followed up in
relation to the functional MELD score for placement on the
list. As a result, patients undergoing liver transplantation
Table 1 - General characteristics of transplant procedures stratified by the median MELD score.
Variable [Missing] Total (278) MELD Functional o 30 (179) MELD Functional 4= 30 (99) p
Male [0] 177 (63.7%) 124 (69.3%) 53 (53.5%) 0.013
Age [0] 52.32 (+- 13.68) 55.68 (+- 12.32) 46.25 (+- 13.99) o0.001
BMI [3] 25.89 (+- 5.96) 25.66 (+- 5.77) 26.3 (+- 6.31) 0.406
Transplant type [0] 0.002
- Standard 217 (78.1%) 143 (79.9%) 74 (74.7%)
- Re-transplant 35 (12.6%) 14 (7.8%) 21 (21.2%)
- Living donor 14 (5%) 13 (7.3%) 1 (1%)
- Double transplant 12 (4.3%) 9 (5%) 3 (3%)
Donor risk index [130] 1.43 (+- 0.31) 1.43 (+- 0.31) 1.44 (+- 0.32) 0.904
Total length of stay [0] 21.39 (+- 25.07) 19.24 (+- 17.32) 25.27 (+- 34.75) 0.108
Length of stay at ICU [0] 9.38 (+- 12.39) 7.61 (+- 9.18) 12.58 (+- 16.27) 0.006
Length of stay at the ward [0] 11.57 (+- 15.78) 11.63 (+- 12.61) 11.45 (+- 20.38) 0.938
Outcome [5] o0.001
- Discharge 181 (66.3%) 128 (72.7%) 53 (54.6%)
- Death 64 (23.4%) 25 (14.2%) 39 (40.2%)
- Re-transplant 28 (10.3%) 23 (13.1%) 5 (5.2%)
Total cost [0] 13613.77 (+- 12293.95) 11542.2 (+- 7891.81) 17359.33 (+- 17090.13) 0.002
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might be sicker than those in other countries as a function of
our higher MELD scores at the time of transplant, which leads
to significantly greater resource utilization and transplanta-
tion cost (6,16,17). Among the available healthcare cost studies
evaluating liver transplants, there has been considerable
variation in study design, financial aspects of transplantation,
and the time period for the cost analysis. For example, the
mean cost of liver transplantation in Europe is lower than in
the United States, with the following rates reported: Italy,
77,475 euros (18); France, 850,515 euros (19); Netherlands,
107,0675 euros for chronic liver disease and 900,792 euros for
acute liver failure (20); Finland, 141,768 euros (17); Germany,
52,570 euros (21); Switzerland, 118,457 euros; the United
Kingdom, 49,920-70,200 euros; and the United States, 156,000-
217,674 euros (22). In contrast, the total cost in Brazil is US$
20,605.01 (23).
It has been previously demonstrated that complications
following liver transplantation significantly increase hospital
costs (7,24,25). As a consequence, the prediction of liver
transplantation costs is closely connected to the prediction of
complications. The severity of liver disease, post-operative
infections, such as cytomegalovirus infections, and complica-
tions involving the biliary tract have all been demonstrated
to contribute to a rise in surgical costs (3). Specifically, in the
pediatric population, complications such as acute cellular
rejection, acute renal failure, hepatic artery thrombosis, and
Table 2 - Specific costs for the operating room, intensive care unit and ward stratified by the median MELD score.
Variable [Missing] Total (278) MELD Functional o 30 (179) MELD Functional 4= 30 (99) p
Operating room cost [0] 5013.18 (+- 1169.68) 4919.48 (+- 1054.35) 5182.59 (+- 1342.73) 0.094
- Human resources [0] 1481.77 (+- 404.22) 1514.28 (+- 432.86) 1422.99 (+- 340.71) 0.054
- High-cost supplies [0] 1451.69 (+- 264.66) 1477.98 (+- 222.4) 1404.14 (+- 323.41) 0.045
- Drugs [0] 930.91 (+- 506.62) 898.57 (+- 465.91) 989.37 (+- 570.81) 0.178
- Materials [0] 466.99 (+- 449.65) 444.11 (+- 453.42) 508.38 (+- 442.02) 0.251
- Blood services [0] 279.47 (+- 456.23) 193.45 (+- 403.5) 435 (+- 504.63) o0.001
- Equipment [0] 168.2 (+- 45.88) 171.89 (+- 49.14) 161.53 (+- 38.68) 0.054
- Labs [0] 93.02 (+- 135.55) 70.54 (+- 96.63) 133.65 (+- 179.95) 0.002
- Gases [0] 23.65 (+- 6.45) 24.17 (+- 6.91) 22.71 (+- 5.44) 0.054
- Room [0] 85.41 (+- 23.3) 87.29 (+- 24.95) 82.03 (+- 19.64) 0.054
- Flowmeter [0] 36 (+- 15.22) 37.2 (+- 13.96) 33.84 (+- 17.11) 0.097
- Hours [0] 9.71 (+- 2.64) 9.91 (+- 2.83) 9.33 (+- 2.23) 0.062
Intensive care unit cost [0] 5792.53 (+- 9508.94) 4145.58 (+- 6381.22) 8770.35 (+- 12949.98) 0.001
- Human resources [0] 2071.29 (+- 2903.29) 1626.99 (+- 2045.01) 2874.63 (+- 3900.85) 0.004
- Dialysis [0] 950.68 (+- 3266.94) 562.42 (+- 2060.89) 1652.67 (+- 4656.15) 0.029
- Drugs [0] 859.47 (+- 2751.78) 572.01 (+- 1880.11) 1379.22 (+- 3815.64) 0.05
- Labs [0] 638.35 (+- 881.47) 426.13 (+- 528.91) 1022.06 (+- 1207.1) o0.001
- Materials [0] 387.67 (+- 571.33) 302.71 (+- 392.33) 541.28 (+- 778.48) 0.005
- Blood services [0] 344.33 (+- 695.75) 257.99 (+- 658.21) 500.43 (+- 736.95) 0.007
- Imaging [0] 177.41 (+- 318.25) 116.59 (+- 202.77) 287.4 (+- 438.88) o0.001
- Equipment [0] 156.11 (+- 218.82) 122.62 (+- 154.13) 216.66 (+- 294.01) 0.004
- Gases [0] 111.95 (+- 156.92) 87.94 (+- 110.53) 155.37 (+- 210.84) 0.004
- Food [0] 68.91 (+- 167.84) 51.38 (+- 143.16) 100.6 (+- 202.05) 0.034
- Per diem cost deprecated [0] 22.45 (+- 31.46) 17.63 (+- 22.16) 31.15 (+- 42.27) 0.004
- Endoscopy [0] 3.91 (+- 32.02) 1.17 (+- 5.02) 8.87 (+- 53.04) 0.153
Ward cost [0] 2808.06 (+- 3820.61) 2477.14 (+- 2640.44) 3406.39 (+- 5294.72) 0.104
- Labs [0] 701.23 (+- 990.82) 588.58 (+- 631.39) 904.9 (+- 1409.14) 0.036
- Human resources [0] 633.78 (+- 849.36) 638.06 (+- 685.22) 626.05 (+- 1089.11) 0.921
- Materials [0] 544.13 (+- 851.38) 511.67 (+- 663.38) 602.84 (+- 1115.39) 0.458
- Drugs [0] 443.79 (+- 1085.53) 319.58 (+- 658.07) 668.37 (+- 1570.05) 0.037
- Dialysis [0] 127.82 (+- 1156.92) 102.77 (+- 1144.93) 173.11 (+- 1182.79) 0.632
- Anatomic pathology [0] 118.76 (+- 89.37) 110.55 (+- 89.29) 133.59 (+- 88.01) 0.039
- Imaging [0] 103.82 (+- 188.16) 82.72 (+- 137.06) 141.96 (+- 252.32) 0.032
- Food [0] 89.79 (+- 197.02) 77.18 (+- 140.16) 112.6 (+- 270.59) 0.227
- Blood services [0] 42.69 (+- 166.77) 17.56 (+- 66.94) 88.12 (+- 259.3) 0.009
- Per diem cost deprecated [0] 19.77 (+- 26.5) 19.91 (+- 21.38) 19.53 (+- 33.98) 0.921
- Endoscopy [0] 6.49 (+- 44.13) 4.72 (+- 38.81) 9.69 (+- 52.47) 0.409
- Equipment [0] 6.44 (+- 36.18) 3.64 (+- 24.57) 11.5 (+- 50.63) 0.149
- Gases [0] 2.23 (+- 30.65) 0.2 (+- 1.78) 5.91 (+- 51.27) 0.271
Total lab cost [0] 1367.11 (+- 1609.41) 1040.91 (+- 966.04) 1956.9 (+- 2253.98) o0.001
OR average medical surgical center cost [0] 78.52 (+- 172.2) 91.47 (+- 182.81) 55.13 (+- 149.19) 0.074
Table 3 - Predicted and adjusted median costs and 95 % confidence intervals.
Cost Component MELD Functional o 30 MELD Functional 4= 30
Total length of stay 16.4 (12.96, 20.77) 16.37 (12.36, 21.68)
Operating room cost 5042.06 (4776.22, 5322.71) 5282.81 (4952.98, 5634.61)
Intensive care unit cost 3342.48 (2513.81, 4444.31) 5651.5 (4026.17, 7932.95)
Ward cost 995.76 (687.1, 1443.09) 1073.51 (690.27, 1669.52)
Total cost 11751.17 (10376.08, 13308.49) 15464.97 (13335.85, 17934)
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infections such as pneumonia accounted for a substantial
increase in hospital costs and, consequently, a decrease in
profit margins (26). However, liver transplants are not the
only procedures with complications contributing to a rise in
costs, and others include pancreas and kidney transplants (27).
Although many of these complications are unpredictable, we
currently know that high MELD scores and previous renal
insufficiency present higher risks of post-transplant compli-
cations (28,29). As expected, when complications develop,
the corresponding length of the hospital stay also increases.
The length of the hospital stay is often cited as an impor-
tant predictor of cost after liver transplantation. In general,
the greater the number of days spent in the hospital after
liver transplant the higher the cost of the overall transplanta-
tion (30–32). It has been previously demonstrated that the
length of the hospital stay is one of the main determinants of
overall hospital fees for surgical patients (33). However, as
some of our models have shown, the impact of the length of
stay on cost is increased by the presence of comorbidities,
with longer stay intervals sometimes only generating a
negligible impact on total hospital costs (34,35). Overall, the
interplay of multiple determinants of cost is important, and
comorbidities play a particularly important role.
Comorbidities, such as viral hepatitis, advanced liver
disease, and portal thrombosis, have all been associated with
higher costs of liver transplant (18,30), and impaired renal
function is one of its main determinants (9,18). Liver trans-
plants are not isolated in this aspect in that comorbidities
have also been shown to increase the cost of kidney trans-
plantation (36). Several authors have used comorbidity indi-
ces to combine different factors in the prediction of outcomes
after liver transplantation. For example, Wasilewicz et al.
adopted the Charlson comorbidity index (37) to predict
survival after liver transplantation (38). The Charlson index
has also been used to predict health care economic endpoints
including cost and resource utilization (39).
Despite filling an important gap in the literature, our study
does have limitations that are mostly associated with its
observational design. First, our cost measures were not unan-
imously validated by different observers and thus intro-
duced a potential classification bias. Second, we did not
include self-reported measures of quality of life or dysfunc-
tion, which could later be used in cost-utility analyses. These
measures constitute an important metric in that they take
into account a direct patient perspective, which is clearly
missing when only cost-driven measurements are used. This
absence in our study was primarily driven by logistical
reasons in that the inclusion of self-reported questionnaires
would significantly increase the complexity of data collec-
tion. Third, despite our best efforts in controlling for missing
rates, some of our variables, such as the DRI, presented par-
ticularly high rates. To minimize this limitation, we utilized
imputation algorithms followed by sensitivity analyses to
ensure that our final conclusions were valid under different
assumptions. Fourth, given that our sample was not randomly
drawn from a larger patient population, its external validity
can be questioned. Although future studies should certainly
aim for larger and more representative samples, our sample
is by no means atypical for its setting, which makes our
conclusions valid for similar populations globally. Fifth,
because the same team performed the transplants through-
out the study period, we cannot evaluate the impact of
trainees on cost. In addition, because we do not have the
breakdown data with respect to ventilator time in the inten-
sive care unit, we cannot further investigate the underlying
reasons behind its cost. Finally, several other statistical
Figure 1 - Tree regression model with individual predictors of total cost.
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approaches could have been used, including machine learn-
ing, which allow for greater predictive performance and
Bayesian Network models that might in turn allow for causal
inferences. However, the former usually requires larger
samples, while the latter is less familiar to clinical audiences
and could therefore lead to confusion in the interpretation of
our results.
In conclusion, our study holds promise in that cost data
can be used to assess future areas that can lead to cost-saving
strategies while maintaining good quality of care (25,27,40–42).
Cost studies are particularly relevant for quality assurance
and safety programs because the improvement of quality
must be conducted within an environment that takes health
economics into account. This is especially important in coun-
tries undergoing cost containment, such as developing coun-
tries and even the United States under escalating cost increases
and the Affordable Care Act. We therefore recommend that
healthcare institutions should undergo continuous cost eval-
uations to determine their main cost drivers and to deter-
mine cost predictors for liver transplantation. Such studies
will allow institutions and public health systems to predict
the cost of each procedure using pre-transplant data from the
recipient and donor.
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’ APPENDIX
Table 4 - Total costs for the operating room, intensive care unit and ward stratified by hepatocellular carcinoma (HCC).
Variable [Missing] Total (168) Hepatocellular carcinoma
absent (114)
Hepatocellular carcinoma
present (54)
p
Operating room cost [0] 5483.51 (+- 941.72) 5583.58 (+- 1002.05) 5272.24 (+- 765.85) 0.028
- Human resources [0] 1470.64 (+- 388.09) 1479.69 (+- 412.76) 1451.54 (+- 332.84) 0.637
- High-cost supplies [0] 1397.31 (+- 329.64) 1356.52 (+- 366.04) 1483.43 (+- 213.51) 0.005
- Drugs [0] 1163.68 (+- 360.56) 1179.29 (+- 393.8) 1130.72 (+- 278.13) 0.36
- Materials [0] 641.65 (+- 439.5) 688.32 (+- 481) 543.15 (+- 317.49) 0.021
- Blood services [0] 383.33 (+- 490.23) 449.83 (+- 515.23) 242.95 (+- 402.1) 0.005
- Equipment [0] 166.94 (+- 44.05) 167.96 (+- 46.85) 164.77 (+- 37.78) 0.637
- Labs [0] 126.41 (+- 161.8) 132.52 (+- 171.87) 113.5 (+- 138.76) 0.445
- Gases [0] 23.48 (+- 6.2) 23.62 (+- 6.59) 23.17 (+- 5.31) 0.637
- Room [0] 84.77 (+- 22.37) 85.29 (+- 23.79) 83.67 (+- 19.19) 0.637
- Flowmeter [0] 31.81 (+- 18.42) 30.13 (+- 19.32) 35.34 (+- 15.95) 0.068
- Hours [0] 9.64 (+- 2.54) 9.7 (+- 2.7) 9.5 (+- 2.18) 0.605
Intensive care unit cost [0] 6933 (+- 11206.92) 8286.71 (+- 12656.89) 4075.16 (+- 6475.2) 0.005
- Human resources [0] 2111.6 (+- 2997.94) 2476.36 (+- 3250.06) 1341.56 (+- 2215.48) 0.009
- Dialysis [0] 1179.06 (+- 3931.16) 1385.49 (+- 4457.92) 743.27 (+- 2457.4) 0.232
- Drugs [0] 1324.37 (+- 3448.97) 1715.37 (+- 4087.75) 498.92 (+- 912.32) 0.003
- Labs [0] 803.39 (+- 970.79) 925.79 (+- 1084.32) 545.01 (+- 602.06) 0.004
- Materials [0] 385.52 (+- 593.81) 448.22 (+- 652.63) 253.16 (+- 420.28) 0.021
- Blood services [0] 501.32 (+- 819.62) 589.8 (+- 882.11) 314.53 (+- 636.63) 0.023
- Imaging [0] 223.22 (+- 362.72) 265.97 (+- 413.13) 132.96 (+- 196.05) 0.005
- Equipment [0] 159.15 (+- 225.95) 186.64 (+- 244.96) 101.11 (+- 166.98) 0.009
- Gases [0] 114.13 (+- 162.04) 133.85 (+- 175.66) 72.51 (+- 119.75) 0.009
- Food [0] 104.33 (+- 207.05) 127.26 (+- 236.15) 55.92 (+- 112.54) 0.009
- Per diem cost deprecated [0] 22.88 (+- 32.49) 26.84 (+- 35.22) 14.54 (+- 24.01) 0.009
- Endoscopy [0] 4.01 (+- 30.25) 5.13 (+- 36.45) 1.66 (+- 6.54) 0.327
Ward cost [0] 3474.9 (+- 4573.5) 3909.41 (+- 5310.57) 2557.6 (+- 2124.99) 0.02
- Labs [0] 903.96 (+- 1146.54) 990.4 (+- 1272.35) 721.48 (+- 800.34) 0.098
- Human resources [0] 643.94 (+- 901.43) 711.36 (+- 1038.87) 501.59 (+- 478.42) 0.075
- Materials [0] 578.51 (+- 978.09) 610.98 (+- 1069.66) 509.96 (+- 753.56) 0.482
- Drugs [0] 666.86 (+- 1327.66) 773.55 (+- 1507.17) 441.64 (+- 796.76) 0.064
- Dialysis [0] 205 (+- 1483.91) 293.62 (+- 1796.56) 17.91 (+- 65.49) 0.105
- Anatomic pathology [0] 137.19 (+- 78.28) 146.62 (+- 88.66) 117.29 (+- 44.19) 0.005
- Imaging [0] 147.62 (+- 217.6) 175.55 (+- 249.42) 88.68 (+- 106.5) 0.002
- Food [0] 133.83 (+- 240.43) 152.23 (+- 282.82) 94.99 (+- 96.6) 0.055
- Blood services [0] 69.45 (+- 210.26) 87.34 (+- 243.03) 31.69 (+- 105.99) 0.04
- Per diem cost deprecated [0] 20.09 (+- 28.13) 22.2 (+- 32.42) 15.65 (+- 14.93) 0.075
- Endoscopy [0] 8.18 (+- 49.27) 11.47 (+- 59.5) 1.22 (+- 5.55) 0.071
- Equipment [0] 10.66 (+- 46.11) 8.48 (+- 44.12) 15.25 (+- 50.17) 0.398
- Gases [0] 3.7 (+- 39.41) 5.32 (+- 47.82) 0.27 (+- 0.76) 0.262
Total labs cost [0] 1752.91 (+- 1823.34) 1975.33 (+- 2063.57) 1283.36 (+- 1032.23) 0.004
OR average medical surgical center cost [0] 2.71 (+- 35.09) 3.99 (+- 42.59) 0 (+- 0) 0.319
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Table 5 - Total costs for the operating room, intensive care unit and ward stratified by primary sclerosing cholangitis (PSC).
Variable [Missing] Total (168) Primary sclerosing
cholangitis absent (161)
Primary sclerosing
cholangitis present (7)
p
Operating room cost [0] 5483.51 (+- 941.72) 5488.48 (+- 957.45) 5369.11 (+- 471.19) 0.554
- Human resources [0] 1470.64 (+- 388.09) 1466.25 (+- 390.07) 1571.59 (+- 349.7) 0.464
- High-cost supplies [0] 1397.31 (+- 329.64) 1420.02 (+- 305.54) 875.12 (+- 450.6) 0.018
- Drugs [0] 1163.68 (+- 360.56) 1164.39 (+- 367.86) 1147.39 (+- 98.25) 0.723
- Materials [0] 641.65 (+- 439.5) 621.46 (+- 419.67) 1106.07 (+- 646) 0.095
- Blood services [0] 383.33 (+- 490.23) 392.59 (+- 496.1) 170.56 (+- 266.48) 0.074
- Equipment [0] 166.94 (+- 44.05) 166.44 (+- 44.28) 178.4 (+- 39.69) 0.464
- Labs [0] 126.41 (+- 161.8) 123.55 (+- 161.13) 192.18 (+- 175.97) 0.347
- Gases [0] 23.48 (+- 6.2) 23.41 (+- 6.23) 25.09 (+- 5.58) 0.464
- Room [0] 84.77 (+- 22.37) 84.52 (+- 22.49) 90.59 (+- 20.16) 0.464
- Flowmeter [0] 31.81 (+- 18.42) 32.66 (+- 17.9) 12.12 (+- 20.69) 0.039
- Hours [0] 9.64 (+- 2.54) 9.61 (+- 2.55) 10.29 (+- 2.29) 0.472
Intensive care unit cost [0] 6933 (+- 11206.92) 7122.8 (+- 11406.97) 2567.62 (+- 1641.24) o0.001
- Human resources [0] 2111.6 (+- 2997.94) 2172.47 (+- 3047.75) 711.69 (+- 264.13) o0.001
- Dialysis [0] 1179.06 (+- 3931.16) 1230.33 (+- 4008.32) 0 (+- 0) o0.001
- Drugs [0] 1324.37 (+- 3448.97) 1354.29 (+- 3514.3) 636.16 (+- 1082.42) 0.17
- Labs [0] 803.39 (+- 970.79) 815.89 (+- 989.6) 515.96 (+- 123.25) 0.002
- Materials [0] 385.52 (+- 593.81) 387.6 (+- 600.9) 337.66 (+- 427.27) 0.775
- Blood services [0] 501.32 (+- 819.62) 518.05 (+- 832.79) 116.46 (+- 151.07) o0.001
- Imaging [0] 223.22 (+- 362.72) 227.44 (+- 369.37) 126.09 (+- 110.93) 0.068
- Equipment [0] 159.15 (+- 225.95) 163.74 (+- 229.71) 53.64 (+- 19.91) o0.001
- Gases [0] 114.13 (+- 162.04) 117.42 (+- 164.73) 38.47 (+- 14.28) o0.001
- Food [0] 104.33 (+- 207.05) 107.83 (+- 210.8) 23.77 (+- 18.2) o0.001
- Per diem cost deprecated [0] 22.88 (+- 32.49) 23.54 (+- 33.02) 7.71 (+- 2.86) o0.001
- Endoscopy [0] 4.01 (+- 30.25) 4.19 (+- 30.89) 0 (+- 0) 0.087
Ward cost [0] 3474.9 (+- 4573.5) 3491.11 (+- 4552.56) 3101.95 (+- 5415.87) 0.857
- Labs [0] 903.96 (+- 1146.54) 911.52 (+- 1155.3) 730 (+- 979.52) 0.649
- Human resources [0] 643.94 (+- 901.43) 660.56 (+- 914.84) 261.55 (+- 346.79) 0.023
- Materials [0] 578.51 (+- 978.09) 550.53 (+- 846.65) 1222.1 (+- 2647.15) 0.528
- Drugs [0] 666.86 (+- 1327.66) 676.64 (+- 1344.47) 441.89 (+- 892.77) 0.527
- Dialysis [0] 205 (+- 1483.91) 213.91 (+- 1515.39) 0 (+- 0) 0.075
- Anatomic pathology [0] 137.19 (+- 78.28) 138.32 (+- 79.37) 111.11 (+- 41.37) 0.144
- Imaging [0] 147.62 (+- 217.6) 149.09 (+- 219.71) 113.92 (+- 170.91) 0.615
- Food [0] 133.83 (+- 240.43) 134.96 (+- 242.13) 107.82 (+- 211.25) 0.751
- Blood services [0] 69.45 (+- 210.26) 67.99 (+- 210.26) 102.96 (+- 223.96) 0.698
- Per diem cost deprecated [0] 20.09 (+- 28.13) 20.61 (+- 28.55) 8.16 (+- 10.82) 0.023
- Endoscopy [0] 8.18 (+- 49.27) 8.5 (+- 50.32) 0.77 (+- 1.32) 0.055
- Equipment [0] 10.66 (+- 46.11) 11.06 (+- 47.06) 1.55 (+- 2.8) 0.015
- Gases [0] 3.7 (+- 39.41) 3.85 (+- 40.25) 0.12 (+- 0.27) 0.241
Total labs cost [0] 1752.91 (+- 1823.34) 1772.06 (+- 1851.72) 1312.53 (+- 927.96) 0.26
OR average medical surgical center cost [0] 2.71 (+- 35.09) 2.82 (+- 35.84) 0 (+- 0) 0.319
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Table 6 - Cost stratified by portal vein thrombosis (PVT).
Variable [Missing] Total (300) Portal vein
thrombosis absent (283)
Portal vein
thrombosis present (17)
p
Operating room cost [12] 4978.97 (+- 1167.67) 4950.58 (+- 1175.22) 5431.46 (+- 958.63) 0.063
- Human resources [12] 1488.68 (+- 407.86) 1486.78 (+- 398.37) 1518.95 (+- 552.15) 0.816
- High-cost supplies [12] 1454.57 (+- 260.45) 1463.17 (+- 247.36) 1317.45 (+- 403.77) 0.16
- Drugs [12] 914.38 (+- 505.31) 906.17 (+- 512.25) 1045.26 (+- 364.42) 0.153
- Materials [12] 450.78 (+- 449.97) 441.29 (+- 455.7) 601.97 (+- 318.92) 0.064
- Blood services [12] 269.76 (+- 451.13) 253.3 (+- 439.74) 532.26 (+- 556.46) 0.058
- Equipment [12] 168.99 (+- 46.3) 168.77 (+- 45.22) 172.42 (+- 62.68) 0.816
- Labs [12] 89.81 (+- 134.24) 89.24 (+- 137.32) 98.91 (+- 70.21) 0.615
- Gases [12] 23.76 (+- 6.51) 23.73 (+- 6.36) 24.25 (+- 8.82) 0.816
- Room [12] 85.81 (+- 23.51) 85.7 (+- 22.96) 87.56 (+- 31.83) 0.816
- Flowmeter [12] 36.23 (+- 14.99) 36.46 (+- 14.75) 32.43 (+- 18.54) 0.391
- Hours [12] 9.75 (+- 2.67) 9.74 (+- 2.61) 9.94 (+- 3.61) 0.822
Intensive care unit cost [12] 5601.05 (+- 9396.4) 5546.73 (+- 9370.92) 6466.91 (+- 10051.54) 0.718
- Human resources [12] 2006.58 (+- 2872.67) 1986.92 (+- 2826.92) 2319.98 (+- 3613.45) 0.714
- Dialysis [12] 917.67 (+- 3214.25) 908.12 (+- 3241.82) 1069.91 (+- 2819.12) 0.823
- Drugs [12] 829.63 (+- 2708.01) 841.6 (+- 2782.69) 638.76 (+- 911.32) 0.47
- Labs [12] 616.21 (+- 873.84) 607.71 (+- 876.75) 751.78 (+- 839.36) 0.502
- Materials [12] 375.61 (+- 564.89) 376.59 (+- 561.57) 360.05 (+- 633.92) 0.918
- Blood services [12] 332.37 (+- 686.43) 306.5 (+- 640.4) 744.78 (+- 1157.3) 0.141
- Imaging [12] 171.25 (+- 314.34) 172.11 (+- 319.26) 157.56 (+- 228.49) 0.807
- Equipment [12] 151.23 (+- 216.51) 149.75 (+- 213.06) 174.85 (+- 272.35) 0.714
- Gases [12] 108.46 (+- 155.27) 107.39 (+- 152.79) 125.4 (+- 195.31) 0.714
- Food [12] 66.52 (+- 165.38) 64.7 (+- 163.98) 95.52 (+- 189.46) 0.521
- Per diem cost deprecated [12] 21.74 (+- 31.13) 21.53 (+- 30.63) 25.14 (+- 39.16) 0.714
- Endoscopy [12] 3.77 (+- 31.46) 3.81 (+- 32.39) 3.18 (+- 7.29) 0.812
Ward cost [12] 2714 (+- 3786.2) 2767.54 (+- 3878.21) 1860.49 (+- 1583.63) 0.053
- Labs [12] 676.9 (+- 981.84) 688.96 (+- 1005.01) 484.73 (+- 453.71) 0.116
- Human resources [12] 613.65 (+- 841.18) 623.53 (+- 856.75) 456.13 (+- 526.96) 0.238
- Materials [12] 526.73 (+- 841.46) 533.87 (+- 860.12) 412.93 (+- 449.17) 0.327
- Drugs [12] 428.38 (+- 1069.56) 444.29 (+- 1099.02) 174.78 (+- 254.29) 0.004
- Dialysis [12] 123.38 (+- 1136.82) 131.12 (+- 1171.63) 0 (+- 0) 0.067
- Anatomic pathology [12] 114.63 (+- 90.46) 113.8 (+- 92.17) 127.86 (+- 56.74) 0.354
- Imaging [12] 100.21 (+- 185.83) 100.47 (+- 189.94) 96.08 (+- 102.88) 0.874
- Food [12] 86.68 (+- 194.26) 88.81 (+- 199.29) 52.61 (+- 73.07) 0.101
- Blood services [12] 41.21 (+- 164.03) 41.39 (+- 167.85) 38.25 (+- 84.63) 0.892
- Per diem cost deprecated [12] 19.15 (+- 26.25) 19.45 (+- 26.73) 14.23 (+- 16.44) 0.238
- Endoscopy [12] 6.26 (+- 43.37) 6.49 (+- 44.69) 2.61 (+- 4.92) 0.191
- Equipment [12] 6.22 (+- 35.56) 6.59 (+- 36.63) 0.25 (+- 0.92) 0.005
- Gases [12] 2.16 (+- 30.12) 2.29 (+- 31.04) 0.03 (+- 0.08) 0.232
Total labs cost [12] 1319.69 (+- 1600.83) 1322.7 (+- 1637.99) 1271.71 (+- 830.38) 0.822
OR average medical surgical center cost [12] 91.59 (+- 182.71) 97.34 (+- 186.87) 0 (+- 0) o0.001
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Table 7 - Cost stratified by death.
Variable [Missing] Total (261) Alive (199) Dead (62) p
Operating room cost [0] 5089.3 (+- 1160.99) 4964.38 (+- 1082.93) 5490.26 (+- 1313.13) 0.005
- Human resources [0] 1479.35 (+- 404.54) 1452.69 (+- 334.99) 1564.91 (+- 568.81) 0.144
- High-cost supplies [0] 1446.28 (+- 272.29) 1432.64 (+- 290.3) 1490.05 (+- 199.77) 0.081
- Drugs [0] 961.92 (+- 507.6) 952.4 (+- 499.44) 992.48 (+- 535.99) 0.603
- Materials [0] 497.41 (+- 447.46) 509.98 (+- 477.41) 457.07 (+- 333.8) 0.331
- Blood services [0] 297.67 (+- 465.09) 218.53 (+- 372.54) 551.69 (+- 620.88) o0.001
- Equipment [0] 167.93 (+- 45.92) 164.9 (+- 38.03) 177.64 (+- 64.57) 0.144
- Labs [0] 98.47 (+- 138.07) 96.43 (+- 129.06) 104.99 (+- 164.74) 0.709
- Gases [0] 23.61 (+- 6.46) 23.19 (+- 5.35) 24.98 (+- 9.08) 0.144
- Room [0] 85.28 (+- 23.32) 83.74 (+- 19.31) 90.21 (+- 32.79) 0.144
- Flowmeter [0] 35.59 (+- 15.61) 35.38 (+- 15.81) 36.25 (+- 15.06) 0.693
- Hours [0] 9.69 (+- 2.65) 9.51 (+- 2.19) 10.27 (+- 3.71) 0.127
Intensive care unit cost [0] 6047.92 (+- 9749.58) 5158.58 (+- 9138.43) 8902.42 (+- 11100.42) 0.018
- Human resources [0] 2119.51 (+- 2972.93) 1829.6 (+- 2410.3) 3050.05 (+- 4202.38) 0.033
- Dialysis [0] 1012.6 (+- 3362.71) 863.27 (+- 3407.62) 1491.88 (+- 3193.76) 0.186
- Drugs [0] 915.45 (+- 2831.25) 756.93 (+- 2708.06) 1424.24 (+- 3165) 0.138
- Labs [0] 673.74 (+- 896.9) 615.13 (+- 872.88) 861.86 (+- 953.09) 0.073
- Materials [0] 396.05 (+- 585.39) 357.5 (+- 516.21) 519.82 (+- 758.43) 0.119
- Blood services [0] 366.75 (+- 712.36) 246.94 (+- 577.45) 751.32 (+- 939.92) o0.001
- Imaging [0] 188.97 (+- 325.13) 164.02 (+- 323.12) 269.05 (+- 321.14) 0.027
- Equipment [0] 159.74 (+- 224.07) 137.89 (+- 181.66) 229.88 (+- 316.73) 0.033
- Gases [0] 114.56 (+- 160.69) 98.89 (+- 130.28) 164.86 (+- 227.14) 0.033
- Food [0] 73.4 (+- 172.29) 67.62 (+- 176.51) 91.94 (+- 157.89) 0.306
- Per diem cost deprecated [0] 22.97 (+- 32.21) 19.83 (+- 26.12) 33.05 (+- 45.54) 0.033
- Endoscopy [0] 4.16 (+- 33.03) 0.95 (+- 4.44) 14.48 (+- 66.67) 0.116
Ward cost [0] 2947.75 (+- 3897.26) 3457.53 (+- 4191.26) 1311.52 (+- 2037.1) o0.001
- Labs [0] 741.75 (+- 1008.6) 915.29 (+- 1083.16) 184.74 (+- 337.78) o0.001
- Human resources [0] 654.23 (+- 867.59) 795.28 (+- 930.49) 201.5 (+- 353.16) o0.001
- Materials [0] 563.01 (+- 872.19) 656.95 (+- 898.61) 261.48 (+- 707.2) o0.001
- Drugs [0] 472.7 (+- 1114.32) 527.42 (+- 1168.3) 297.04 (+- 906.12) 0.107
- Dialysis [0] 136.14 (+- 1193.66) 168.91 (+- 1363.52) 30.97 (+- 153.5) 0.163
- Anatomic pathology [0] 126.49 (+- 86.76) 116.92 (+- 87.15) 157.21 (+- 78.55) o0.001
- Imaging [0] 110.58 (+- 192.27) 122.9 (+- 200.8) 71.02 (+- 156.86) 0.036
- Food [0] 95.64 (+- 201.98) 114.32 (+- 224.5) 35.7 (+- 74.07) o0.001
- Blood services [0] 45.47 (+- 171.77) 41.29 (+- 164.98) 58.88 (+- 192.78) 0.518
- Per diem cost depreciated [0] 20.41 (+- 27.07) 24.81 (+- 29.03) 6.29 (+- 11.02) o0.001
- Endoscopy [0] 6.91 (+- 45.52) 7.08 (+- 45.46) 6.39 (+- 46.09) 0.918
- Equipment [0] 6.86 (+- 37.31) 8.92 (+- 42.53) 0.25 (+- 2.01) 0.005
- Gases [0] 2.38 (+- 31.63) 3.11 (+- 36.22) 0.03 (+- 0.18) 0.232
Total labs cost [0] 1444.81 (+- 1628.83) 1559.98 (+- 1766.12) 1075.17 (+- 1000.74) 0.007
OR average medical surgical center cost [0] 54.02 (+- 147.42) 63.99 (+- 158.54) 22.01 (+- 98.39) 0.013
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